Investor relations

Depositphotos_7851978_original copyBoulos & Cooper Pharmaceuticals own the intellectual property for a novel class of antimicrobials with promise in three different fields of use; antibiotic drugs, antimicrobial coatings for medical devices and antibiotic creams.

Our antimicrobials are part of a new class and our patents cover a large and previously unexplored chemical space. Our candidates target the highly conserved MscL channel in bacteria; meaning resistance emergence is less likely to occur, translating to higher returns for investors. Our candidates have high efficacy against a number of bacterial species and are well tolerated. The synthesis of our candidates is high yielding using well-established chemistry and readily available starting materials.

If you are interested in a partnership or would like to find out more our research and development, please contact us.